Tiotropium + Aclidinium
ApprovedCompleted 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Pulmonary Disease, Chronic Obstructive
Conditions
Pulmonary Disease, Chronic Obstructive
Trial Timeline
Feb 1, 2014 → Jul 1, 2015
NCT ID
NCT02039050About Tiotropium + Aclidinium
Tiotropium + Aclidinium is a approved stage product being developed by Almirall for Pulmonary Disease, Chronic Obstructive. The current trial status is completed. This product is registered under clinical trial identifier NCT02039050. Target conditions include Pulmonary Disease, Chronic Obstructive.
What happened to similar drugs?
20 of 20 similar drugs in Pulmonary Disease, Chronic Obstructive were approved
Approved (20) Terminated (1) Active (0)
✅Arformoterol Tartrate Inhalation Solution + Arformoterol Tartrate Inhalation Solution + PlaceboSumitomo PharmaApproved
Hype Score Breakdown
Clinical
20
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02039050 | Approved | Completed |
Competing Products
20 competing products in Pulmonary Disease, Chronic Obstructive